Every artificial intelligence-assisted conclusion that makes it outside the walls of an R&D organisation is a scientific claim that eventually has to stand on its own

As more and more cell therapies move from experimental treatments to commercial realities, manufacturing remains the primary bottleneck to patient access

How are digital innovations offering a new way of working for contract development and manufacturing organisations?

How are deliberately structured artificial intelligence ecosystems integrating the tools scientists already rely on, enabling innovation while preserving provenance, governance and confidence across the drug discovery and development life cycle?

From target identification and molecular design to process optimisation and quality control, artificial intelligence and machine learning are being positioned as transformative enablers across the pharma landscape. However, as adoption accelerates, it is becoming clear that the impact of these technologies is not determined solely by model sophistication or computational power. Rather, their effectiveness is fundamentally constrained by the availability, quality and structure

How is retrieval-augmented generation aiding smaller biotechs in collating and utilising disparate data systems?

What are co-folding models and how is their use transforming drug development?

How can pharma companies improve their digital systems while maintaining regulatory compliance, and ensure the two teams work together cohesively?

How is artificial intelligence, when delivered through software as a service platforms, unlocking real business outcomes for pharmaceutical manufacturers, from faster batch release and smarter investigations to smoother tech transfers and enterprise-wide compliance?

How is artificial intelligence changing the way drug discovery and development is enacted across the sector, yielding not only impressive potential, but also clinically validated pharma products?

Artificial intelligence-powered de novo protein design is opening new pathways in biologics discovery, allowing researchers to create synthetic proteins beyond nature’s existing repertoire

For decades, bringing a drug from concept to patient access has been an expensive, convoluted and often uncertain journey. The traditional drug discovery process relies heavily on trial and error, biological hypotheses and rigid scientific processes. Various challenges significantly prolong the drug discovery process, ultimately slowing the pace of innovation and delivery of treatment for patients. Today, the integration of artificial intelligence into the drug discovery proc